Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Credit Suisse Maintains Outperform on Ikena Oncology, Lowers Price Target to $13

Credit Suisse analyst Judah Frommer maintains Ikena Oncology (NASDAQ:IKNA) with a Outperform and lowers the price target from $16 to $13.

byBenzinga Newsdesk

March 15, 2023

1 minute read

Credit Suisse analyst Judah Frommer maintains Ikena Oncology (NASDAQ:IKNA) with a Outperform and lowers the price target from $16 to $13.

Raymond James Says PTC Therapeutics’ CHMP Backing Is ‘Under Exceptional Circumstances’ What’s Next

By Vandana Singh

Today, 6:04 PM

Last week, PTC Therapeutics Inc’s (NASDAQ:PTCT) Upstaza (PTC-AADC; AAV2-based DDC gene therapy) received a CHMP opinion for approval under exceptional circumstances, says Raymond…

PTCT

Report Finds Increased Adoption of Digital Out-of-Home Advertising in Post-Pandemic Economy

Today, 6:04 PM

Image Provided By Flickr

ALF

Global
News

FB Russian Communications Regulator Says It Will Impose Restrictions On Access To Instagram On March 14

By Bill Haddad

Today, 6:04 PM

-Reuters

The 10 Most Searched Things In 2022: How Wordle, Queen Elizabeth, Mega Millions And Jeffrey Dahmer Stack Up In Google Search Rankings

By Chris Katje

Today, 6:04 PM

As the new year begins, Benzinga takes a look back at new trends that emerged in 2022 and topics that drew the most online search interest.

GOOG

Credit Suisse Maintains Outperform on Ikena Oncology, Lowers Price Target to $13

Related Posts

Raymond James Says PTC Therapeutics’ CHMP Backing Is ‘Under Exceptional Circumstances’ What’s Next

Report Finds Increased Adoption of Digital Out-of-Home Advertising in Post-Pandemic Economy

FB Russian Communications Regulator Says It Will Impose Restrictions On Access To Instagram On March 14

The 10 Most Searched Things In 2022: How Wordle, Queen Elizabeth, Mega Millions And Jeffrey Dahmer Stack Up In Google Search Rankings